Filippo Pederzoli, Michela Riba, Chiara Venegoni, Laura Marandino, Marco Bandini, Elisa Alchera, Irene Locatelli, Daniele Raggi, Patrizia Giannatempo, Paolo Provero, Dejan Lazarevic, Marco Moschini, Roberta Lucianò, Andrea Gallina, Alberto Briganti, Francesco Montorsi, Andrea Salonia, Andrea Necchi, Massimo Alfano
Neoadjuvant pembrolizumab has been shown to be a valid treatment for patients affected by muscle-invasive bladder cancer (MIBC), as demonstrated in the PURE-01 clinical trial (NCT02736266). Among the tumor-extrinsic factors influencing immunotherapy efficacy, extensive data highlighted that the microbiome is a central player in immune-mediated anticancer activity. This report aimed to investigate the composition and role of stool microbiome in patients enrolled in the PURE-01 clinical trial. An orthotopic animal model of bladder cancer (MB49-Luc) was used to support some of the findings from human data...
January 5, 2024: European Urology